Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Company price
0.3602 USD 0.00(0%)
Last update at 2026-11-19T21:00:00Z
VOLUME
618
Market Cap
142.50M

Momentum Score

…

AnGes, Inc. engages in the research and development of gene-based medicines. It develops HGF gene therapy product for the treatment of chronic arterial occlusive disease; NF-KB decoy oligonucleotide for chronic discogenic lumbar back pain; and DNA vaccines for the treatment of hypertension, as well as tie2 agonists for COVID-19/ARDS and drugs for chronic hepatitis B. AnGes, Inc. was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. The company was incorporated in 1999 and is headquartered in Ibaraki, Japan.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.34
Low
0.36
High
52 Week Price Range
0.34
Low
0.36
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

AnGes Inc is a Japan-based biotechnology company developing gene therapies and DNA-based therapeutics, including plasmid DNA vaccines and angiogenic gene treatments. Long-term growth may be supported by clinical progress and regulatory approvals across its development programs, licensing or partnerships that enable commercialization, and demand from aging populations with unmet vascular and infectious disease needs, which may appeal to investors seeking exposure to genetic-therapy platforms.
Principal investment risks are high clinical and regulatory failure probability, limited commercial revenue necessitating additional financing, and competitive or technological shifts that could erode program value.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.36
Dividend Yield
-
Revenue TTM
874.00M
Revenue Per Share
2.46
Gross Profit TTM
320.00M
Debt / Equity
-
ROE
-195.87%
Net Debt
-
ROCE
-162.70%
Diluted EPS TTM
-0.79

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -5236.58M -27643.67M -7471.41M - -13735.29M
Net income -5123.27M -28128.98M -7437.61M - -13675.59M
Selling general administrative 1912.60M 5573.76M 5814.01M - 4855.70M
Gross profit 320.38M 247.70M 19.45M - 7.43M
Reconciled depreciation 53.84M 3371.64M 3109.06M - 2426.08M
Ebit - - - -16316.00M -15632.00M
Ebitda - - - - -13206.00M
Operating income -5145.39M -9109.44M -11967.50M - -15632.08M
Other operating expenses - - - - 256.00M
Interest expense - - - - 0.00M
Tax provision -113.31M 485.32M -33.81M - -59.71M
Interest income 14.86M 4.45M 8.41M - 0.57M
Net interest income -27.48M -53.13M -11.80M - -97.37M
Income tax expense - - - -2.00M -59.00M
Total revenue 874.12M 643.64M 152.99M - 64.15M
Total operating expenses 6019.51M 9753.08M 12120.49M - 15696.23M
Cost of revenue 553.74M 395.94M 133.54M - 56.72M
Net income from continuing ops -5123.27M -28128.98M -7437.61M - -13675.59M
Net income applicable to common shares - - - -14714.00M -13675.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 5405.98M 4668.60M 28892.54M 38820.71M 45455.75M
Intangible assets 7.63M 9.66M - - -
Other current assets 28.50M 9.91M 32.60M 361.00M 1786.00M
Total liab 2329.90M 2512.01M 2789.37M 8395.31M 6821.01M
Total stockholder equity 3076.08M 2156.59M 26103.17M 30425.41M 38634.74M
Other current liab 13.11M 14.18M 15.44M 6520.00M 5933.00M
Common stock - - - 35146.00M 33359.00M
Capital stock 40228.66M 37255.89M 35053.89M 35146.37M 33359.57M
Retained earnings -51637.86M -46514.59M -18385.61M -27150.00M -12435.00M
Other liab - - - 80.00M 89.00M
Good will - 0.00M 21746.09M 23254.47M 22675.74M
Other assets - - - 160.00M 111.00M
Cash 1882.01M 1707.76M 4160.42M 11035.10M 17899.34M
Total current liabilities 2243.47M 2313.28M 2493.16M 7323.00M 6733.00M
Other stockholder equity - - - 4960.00M 2029.00M
Property plant equipment - - - 1410.00M 193.00M
Total current assets 4386.54M 3542.61M 5921.28M 12896.00M 21426.00M
Net tangible assets - - - 7169.00M 15958.00M
Net receivables 121.62M 85.23M 26.53M 401.00M 429.00M
Inventory 1746.52M 1429.18M 1566.14M 1008.00M 1223.00M
Accounts payable 542.96M 307.94M 426.45M 553.00M 720.00M
Non currrent assets other 2.88M 0.95M 1.51M 81.25M 73.48M
Non current assets total 1019.44M 1125.99M 22971.26M 25924.25M 24029.60M
Capital lease obligations 54.37M 272.45M 362.68M 1155.71M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 0.00M -56.95M -356.65M -74.00M -74.00M
Change to liabilities - - - -317.00M -453.00M
Total cashflows from investing activities - - - -97.00M -154.00M
Net borrowings 0.00M 1300.00M 0.00M - -
Total cash from financing activities - - - 3572.00M 17378.00M
Change to operating activities - - - 641.00M 261.00M
Net income -5123.27M -28128.00M 1067.00M -14714.00M -13675.00M
Change in cash 168.40M -2464.49M -6877.52M -6866.00M 6298.00M
Begin period cash flow 1627.67M 4092.16M 10969.68M 17835.70M 11537.03M
End period cash flow 1796.07M 1627.67M 4092.16M - 17835.70M
Total cash from operating activities -5750.37M -6612.88M -8745.76M -11214.00M -11380.00M
Issuance of capital stock 5870.21M 3008.40M 2033.14M - 17280.79M
Depreciation 53.84M 3371.64M 3109.06M 2901.00M 2425.00M
Other cashflows from investing activities - - - -4.00M -74.00M
Change to inventory -317.33M 136.95M -557.69M 215.00M -32.00M
Change to account receivables - - - - 2.00M
Sale purchase of stock 0.00M -0.01M 0.00M - -0.32M
Change to netincome - - - 62.00M 152.00M
Capital expenditures 14.32M 77.45M 89.33M 19.00M 80.00M
Change in working capital -622.53M -374.53M -5106.12M - 194.05M
Stock based compensation 0.35M 5.19M 42.43M - 60.65M
Other non cash items 22.31M 46.90M 8.71M - 62.58M
Free cash flow -5764.69M -6690.33M -8835.09M - -11478.14M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
AMGXF
AnGes Inc
-
-%
0.36 - - 0.16 0.73 38.42 -0.01
NVO
Novo Nordisk A/S
-1.06
2.73%
37.81 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-5.64
1.08%
515.02 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
-
-%
920.69 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

AnGes Inc

AnGes, Inc. engages in the research and development of gene-based medicines. It develops HGF gene therapy product for the treatment of chronic arterial occlusive disease; NF-KB decoy oligonucleotide for chronic discogenic lumbar back pain; and DNA vaccines for the treatment of hypertension, as well as tie2 agonists for COVID-19/ARDS and drugs for chronic hepatitis B. AnGes, Inc. was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. The company was incorporated in 1999 and is headquartered in Ibaraki, Japan.

Saito Bio-Incubator, Ibaraki, Japan, 567-0085

81 72 643 3590

56

Name Title Year Born
Dr. Ei Yamada M.D., Ph.D. CEO, Pres & Representative Director 1950
Naoya Sato Director of Corp. Devel. & Director NA
Dr. Ei Yamada M.D., Ph.D. CEO, President & Representative Director 1950
Mr. Naoya Sato Director of Corporate Development & Director 1960
Yuka Murakami Accounting Department Manager NA
Mr. Naoya Sato Director of Administration & Director 1960

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…